Grace Therapeutics, Inc. (GRCE)
EBITDA Margin
-13016.77%
TTM · Period ending:
GRCE EBITDA Margin
Latest reported-13016.77%period ending
Latest reported-13016.77%period ending
GRCE TTM EBITDA Margin (-8417.76% → -13016.77%)
TTM ebitda margin
High-resolution chart · PNG
GRCE ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -13,016.7725% | |
| -6,838.2089% | |
| -6,787.7994% | |
| -7,425.6489% | |
| 15,975.5352% | |
| -36,050.8387% | |
| -28,022.227% | |
| -18,418.6132% | |
| -10,376.2815% | |
| -2,375.8774% | |
| 465.6% | |
| -928.3483% | |
| 225.8877% | |
| -15.0283% | |
| -2,244.6567% | |
| -1,080.7326% | |
| -1,970.7368% | |
| -2,694.3434% | |
| -1,037.9656% | |
| -915.4516% | |
| -852.8816% | |
| -858.4421% | |
| -2,426.763% | |
| -23,054.873% | |
| -5,993.6835% | |
| -4,780.1079% | |
| -3,570.2531% | |
| -2,605.6332% | |
| -8,417.7617% |